% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Horak:125283,
      author       = {P. Horak$^*$ and B. Klink$^*$ and C. Heining$^*$ and S.
                      Gröschel$^*$ and B. Hutter$^*$ and M. A. Fröhlich$^*$ and
                      S. Uhrig$^*$ and D. Hübschmann$^*$ and M. Schlesner$^*$ and
                      R. Eils$^*$ and D. Richter$^*$ and K. Pfütze$^*$ and C.
                      Geörg$^*$ and B. Meißburger$^*$ and S. Wolf$^*$ and A.
                      Schulz$^*$ and R. Penzel and E. Herpel and M. Kirchner$^*$
                      and A. Lier$^*$ and V. Endris and S. Singer and P.
                      Schirmacher$^*$ and W. Weichert$^*$ and A. Stenzinger$^*$
                      and R. Schlenk$^*$ and E. Schröck$^*$ and B. Brors$^*$ and
                      C. von Kalle$^*$ and H. Glimm$^*$ and S. Fröhling$^*$},
      title        = {{P}recision oncology based on omics data: {T}he {NCT}
                      {H}eidelberg experience.},
      journal      = {International journal of cancer},
      volume       = {141},
      number       = {5},
      issn         = {0020-7136},
      address      = {Bognor Regis},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2017-01421},
      pages        = {877 - 886},
      year         = {2017},
      abstract     = {Precision oncology implies the ability to predict which
                      patients will likely respond to specific cancer therapies
                      based on increasingly accurate, high-resolution molecular
                      diagnostics as well as the functional and mechanistic
                      understanding of individual tumors. While molecular
                      stratification of patients can be achieved through different
                      means, a promising approach is next-generation sequencing of
                      tumor DNA and RNA, which can reveal genomic alterations that
                      have immediate clinical implications. Furthermore, certain
                      genetic alterations are shared across multiple histologic
                      entities, raising the fundamental question of whether tumors
                      should be treated by molecular profile and not tissue of
                      origin. We here describe MASTER (Molecularly Aided
                      Stratification for Tumor Eradication Research), a clinically
                      applicable platform for prospective, biology-driven
                      stratification of younger adults with advanced-stage cancer
                      across all histologies and patients with rare tumors. We
                      illustrate how a standardized workflow for selection and
                      consenting of patients, sample processing,
                      whole-exome/genome and RNA sequencing, bioinformatic
                      analysis, rigorous validation of potentially actionable
                      findings, and data evaluation by a dedicated molecular tumor
                      board enables categorization of patients into different
                      intervention baskets and formulation of evidence-based
                      recommendations for clinical management. Critical next steps
                      will be to increase the number of patients that can be
                      offered comprehensive molecular analysis through
                      collaborations and partnering, to explore ways in which
                      additional technologies can aid in patient stratification
                      and individualization of treatment, to stimulate clinically
                      guided exploratory research projects, and to gradually move
                      away from assessing the therapeutic activity of targeted
                      interventions on a case-by-case basis toward controlled
                      clinical trials of genomics-guided treatments.},
      cin          = {G100 / L301 / G240 / L101 / G200 / B080 / B069 / W190 /
                      L701},
      ddc          = {610},
      cid          = {I:(DE-He78)G100-20160331 / I:(DE-He78)L301-20160331 /
                      I:(DE-He78)G240-20160331 / I:(DE-He78)L101-20160331 /
                      I:(DE-He78)G200-20160331 / I:(DE-He78)B080-20160331 /
                      I:(DE-He78)B069-20160331 / I:(DE-He78)W190-20160331 /
                      I:(DE-He78)L701-20160331},
      pnm          = {317 - Translational cancer research (POF3-317)},
      pid          = {G:(DE-HGF)POF3-317},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:28597939},
      doi          = {10.1002/ijc.30828},
      url          = {https://inrepo02.dkfz.de/record/125283},
}